Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentPasi A. Jänne, Melissa L. Johnson, David Sommerhalder et al.|Molecular Cancer Therapeutics|2023Cited by 60
Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancerPierre-Étienne Heudel, Jean-Luc Soubirou, Sylvie Chabaud et al.|ESMO Open|2021Cited by 35